biostudies-literatureUnknown100(2)Braulke FInternational Prognostic Scoring Systems are used to determine the individual risk profile of myelodysplastic syndrome patients. For the assessment of International Prognostic Scoring Systems, an adequate chromosome banding analysis of the bone marrow is essential. Cytogenetic information is not available for a substantial number of patients (5%-20%) with dry marrow or an insufficient number of metaphase cells. For these patients, a valid risk classification is impossible. In the study presented here, the International Prognostic Scoring Systems were validated based on fluorescence in situ hybridization analyses using extended probe panels applied to cluster of differentiation 34 positive (CD34(+)) peripheral blood cells of 328 MDS patients of our prospective multicenter German diagnostic Haematologica205-13https://www.ebi.ac.uk/biostudies/studies/S-EPMC4803133biostudies-literatureValidation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.PMC4803133Pfeilstocker MMallo MHildebrandt BBrummendorf THHaase DBennett JMMuller-Thomas CSchanz JSlovak MLValent PLubbert MShirneshan KFonatsch CNosslinger TGotze KTrumper LStauder RPlatzbecker UGreenberg PLSole FGerming UOhyashiki KAul CLe Beau MMHofmann WKGiagounidis AABraulke FNolte FTuchler HSperr WRfalseValidation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.International Prognostic Scoring Systems are used to determine the individual risk profile of myelodysplastic syndrome patients. For the assessment of International Prognostic Scoring Systems, an adequate chromosome banding analysis of the bone marrow is essential. Cytogenetic information is not available for a substantial number of patients (5%-20%) with dry marrow or an insufficient number of metaphase cells. For these patients, a valid risk classification is impossible. In the study presented here, the International Prognostic Scoring Systems were validated based on fluorescence in situ hybridization analyses using extended probe panels applied to cluster of differentiation 34 positive (CD34(+)) peripheral blood cells of 328 MDS patients of our prospective multicenter German diagnostic 2015-01-01T00:00:00Z2015 Feb2025-05-29T21:25:25.133Z2019-03-27T03:10:04ZS-EPMC48031332534452210.3324/haematol.2014.110452